Can you take Gazyva with Loncastuximab tesirine?

The obinutuzumab in Gazyva has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Severe neutropenia, thrombocytopenia, and anemia have been documented with the use of anti-CD20 antibodies. Monitor complete blood counts during and after therapy according to clinical guidelines.

The obinutuzumab in Gazyva has a major potential interaction with Infection.

Serious infections, including reactivation of viral infections, have been reported with the use of anti-CD20 antibodies. JC virus infections resulting in progressive multifocal leukoencephalopathy (PML) have been reported in patients treated with these agents. A diagnosis of PML should be considered in any patient presenting with new-onset neurological manifestations, and a consultation with a neurologist is recommended. Care should be exercised when giving these drugs to patients with a history of recurring or chronic infections as they are at an increased risk of infections. Do not start therapy in patients with an active infection.

The obinutuzumab in Gazyva has a major potential interaction with Infectious Hepatitis.

The use of anti-CD20 antibodies has caused reactivation of hepatitis B virus, in some cases with fatal outcomes. It is recommended to screen all patients for hepatitis B virus infection before initiating treatment. Monitor patients during, and after several months for hepatitis B virus infection according to clinical practice. Discontinue these agents immediately and institute appropriate treatment if patients develop reactivation of hepatitis B virus while on therapy.

Loncastuximab tesirine has a moderate potential interaction with Liver Disease.

Patients with mild hepatic impairment should be monitored for a potential increase of adverse effects when using loncastuximab tesirine. This drug has not been studied in patients with moderate or severe hepatic impairment.

The obinutuzumab in Gazyva has a moderate potential interaction with Pulmonary Impairment.

Patients with a prior history of cardiac or pulmonary disease should be closely monitored during and after the infusion of anti-CD20 antibodies as they can increase the risk of presenting a severe and life-threatening infusion reaction. Therapy with these agents should be permanently discontinued in patients presenting any Grade 4 infusion reactions and for those presenting Grade 3, interrupt therapy and institute treatment according to clinical guidelines. The rate of infusion should be reduced for those patients presenting Grade 1, or 2 reactions.

Loncastuximab tesirine has a moderate potential interaction with Renal Dysfunction.

The effects of severe renal impairment and end-stage renal disease in the pharmacokinetics of loncastuximab tesirine is unknown.

The obinutuzumab in Gazyva has a major potential interaction with Tumor Lysis Syndrome.

Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has occurred in patients receiving certain monoclonal antibodies. Patients with high tumor burden and/or high circulating lymphocyte counts (greater than 25 x 10[9]/L) are at greater risk for developing TLS. Tumor lysis prophylaxis with anti-hyperuricemics and hydration prior to infusion may be recommended or should be considered. Electrolyte abnormalities should be corrected, and renal function and fluid balance should be monitored in patients who develop TLS. It is recommended to monitor for signs/symptoms of TLS, and temporary interruption or discontinuation of therapy might be required.